Researchers publishing in Cell Reports Medicine have described the development of a lipid nanoparticle (LNP) that delivers mRNA to neurons in order to stop the formation of tau aggregates and fight Alzheimer’s disease.

Tau and amyloids

Amyloid beta deposition between neurons and tau aggregation within neurons are both hallmarks of Alzheimer’s disease, and evidence suggests that the latter is potentially more significant than the former [1]. While some potential therapies have been discovered that may disaggregate these tau tangles after they have formed [2], no therapy has yet been approved by the FDA to do this.